New Cancer Breakthrough Just Dropped… And Almost No One Is Talking About It!

New RAS drug cuts death risk 60% and WILL change cancer treatment forever. #Chemotherapy #TargetedTherapy #Daraxonrasib 

--------------------------------------------
Description:
Something new and absolutely amazing just came out in new cancer drug research…

and it’s not getting nearly the attention it should.
This isn’t another “maybe someday” idea—
it’s real Phase 3 clinical trial data and an approval right around the corner.

And it targets one of the hardest problems in cancer:
KRAS, and the entire RAS pathway in general. That covers more than 25% of ALL cancers. Including brain metastases. And it provides a new and relatively easy way to target things that have been very difficult in th epast.

In this breakdown, Dr. Chaplin explains:
• why KRAS has been nearly impossible to treat
• what makes this new approach completely different
• and why this will impact multiple cancers—not just one
• when this drug should be available and what to do in the meantime

If you or someone you care about is dealing with cancer,
this is worth understanding.

--------------------------------------------

Citations:

Press release April 13 https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/ 
2025 MotY https://drughunter.com/articles/daraxonrasib-rmc-6236-the-2025-molecule-of-the-year
RASolute 302 Clinical Trial https://clinicaltrials.gov/study/NCT06625320
More clinical trials https://www.cancer.gov/research/participate/clinical-trials/intervention/daraxonrasib

--------------------------------------------

Inquiries: 

info@elevatingcancertreatment.com

https://elevatingcancertreatment.com

--------------------------------------------

Disclaimer:
The information provided in this podcast is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard or read in this podcast or on this channel.
Reliance on any information provided by Dr. Jay Chaplin or Elevating Cancer Treatment is solely at your own risk. Dr. Jay Chaplin is a scientist and drug developer, not a medical doctor providing patient care. The content presented here reflects general scientific understanding and research, and may not be applicable to your individual health circumstances. Individual medical conditions and treatments vary, and no two situations are exactly alike.
Always consult with your personal healthcare provider before making any decisions about your health or treatment plan.

Transcript

SPEAKER_00 0:00

This is my excited face, and honestly, yours should be excited too. Why? Because something just dropped that most people are completely underestimating, and it is going to change cancer treatment forever. I am not exaggerating. I'm not good at exaggerating. We just got top-line data for the phase 3 clinical trial of a new drug called Diraxon Rasib. What's so special about it? And what are the results? We expected the results to be great, but they are even better than great. They are really, really amazing, especially for pancreatic cancer, which is classically very hard to treat. But here's the much bigger deal. This isn't just a drug for pancreatic cancer, or for one type of cancer mutation. This is a completely new way of targeting one of the hardest pathways in all of cancer. And if this plays out the way it looks right now, it's going to reshape treatment across multiple cancers and provide a completely new way of approaching other hard-to-drug targets, which is a really fancy way of saying pathways that are very difficult to make good drugs against. Some pathways in the cell are very easy to make drugs against, and we've got lots of good drugs for those. We've got tons. And some pathways are massively difficult and usually have no drugs available at all. We'd really like to hit those, we'd really like to expand our repertoire. RAS is in that second group. So in this video, we're breaking down why this drug is so different and promising, who it could help, which is a lot of folks, so you're gonna want to share this with your communities, what this trial actually showed, when the drug will actually be available, and what you can do in the meantime. So let's get into it. Hello and welcome to Bitting Cancer Treatment, where we explain the science and debunk myths to help you navigate your health journey. My background is a little different. Beyond educating about cancer, I'm actually designing new drugs that are defining the future of oncology. This direct hands-on experience offers me a very different perspective of how these cancer treatments work on the body, interact with the cancer cells, and cause side effects. And these are insights that I'm excited to share with you. If that sounds interesting, make sure to like this video, subscribe to the channel, and hit that notification bell so you never miss an update. And please share it if you find it useful. I'm Dr. Jay Chaplin. An important reminder, I'm a PhD, not an MD. The information in this video is education and it's not medical advice. Every cancer is unique and no general information applies to everyone. Please remember that. Always consult with your healthcare provider for guidance on your specific situation. And two quick things. First, as a thank you for being here, I've created a free resource, 10 things to elevate your chemo journey, which you can download from the link below. And second, by signing up, you'll also get updates on that innovative cancer treatment I'm working on. I'm confident it represents a significant advancement in immunotherapy. So please take a moment, download your free guide, and join us in shaping the future of cancer treatment. So on April 13th, 2026, Revolution Medicines put out a press statement for the Rasolute 302 trial, testing Diraxon Rasib in pancreatic cancer. We put a link to it down below as usual. The results? Extremely promising, especially considering that metastatic pancreatic cancer is very hard to treat, and these patients had already failed at least one treatment type, at least one. But the long-term impact goes way, way, way beyond that. To understand why this is such a big deal, we need to talk about KRAS and the RAS pathway in general. KRAS is basically a messenger protein. It takes grow signals from receptors on the surface of a cell, and it passes them along inside the cell to tell it to grow and multiply. Think of it like a relay race, okay? It starts in an off shape attached to a receptor. The receptor gets activated, hands the baton over, the signal over to KRAS, and KRAS changes shape. It falls off because the shape doesn't match the receptor anymore. And it just sort of bounces around and bumps around inside of the cell, looking for something that it does match with, for a new partner with a right new on shape. When it finds it, it sticks to that partner, passes the signal, that baton, onto the next protein in the signaling cascade, and it goes off to do its thing. When that happens, KRAS swaps back to the off shape to repeat the cycle all over again. It goes back and snuggles up to a receptor on the cell surface again. That's how cells know when to grow and multiply. Faithful processing of this signal. Now, here's the problem. KRAS is one of the most commonly mutated proteins in all of cancer. We're talking 95% of pancreatic cancers, 40% of colorectal cancer, 30% of non-small cell lung cancer, and 25% of melanomas. Overall, about 20-25% of all cancers, all cancers, are driven by some kind of a RAS mutation, and KRAS makes up about 80% of that group. What does that mean? That's 3.4 million new cases of cancer every year driven by KRAS mutations. And historically, this pathway has been notoriously hard to target. So this has been known. KRAS driver mutations have been known since the early 80s. And back in 2021, we got our first breakthrough with Soda Rasib. It's a drug targeting specific KRAS mutations. Just one, G12C. The 12th amino acid, which is normally a glycine, has been changed into a cysteine. And that version is always on. It never sticks to the receptor, it's always looking for its downstream partner. It's always signaling grow, grow, grow, grow, grow, grow now, grow, no matter what the receptors are telling it. Blocking that was a big milestone. But it only works for a small subset of patients. Huge value for a small fraction of people. About 43% of people with non-small cell lung cancer have that KRAS mutation. But only 13% of all cancers with a KRAS mutation have G12C. There are a lot of other ones. Most KRAS mutations are different. There's a ton of them. Beyond that G12C mutation in KRAS, there's G12D, V, and A in pancreatic, colorectal, and non-small cell lung cancer. There's G13D and G13C in colorectal cancers. There's four different kinds of Q61 mutations in chalangiocarcinomas, pancreatic cancer, and colorectal cancer. And beyond that, there are mutations in other family members, HRAS and NRAS. And sometimes the RAS part isn't mutated at all. It's just constantly activated by upstream signaling from the receptors themselves that are always on. Like overexpressed or mutated versions of PDGFR, EGFR, CSF1R, Integrens, HER2, or fusions like BCR Abel. So Soda RASIP is great, and it only targets that specific G12C mutation in KRAS. It does one job and it does it incredibly well. Super value. But there are many more mutations and disease states than that. So the problem there is massive. There are way too many mutations to target easily, too many variations, and too many ways to activate this pathway that we would really like to suppress because it's such a common problem in cancer. So, this is where Diraxon Rasib changes the game. Most drugs, like soda racib, work like a key fitting into a lock. Most drugs are literally designed to fit into pockets of enzymes where they work on their target, a substrate, often mimicking the structure of that thing they were supposed to work on. You design a drug for a specific mutation, like that KRAS G12C, for the specific little binding pocket it has, the keyhole. This is the way that almost all targeted therapies are designed, and we talked about that and why you need biomarker testing to see if you're a match in this episode. What this means is that while that targeted therapy is very potent for the particular type, you need a different drug for each and every mutation. That's incredibly difficult, very slow, and very expensive. The drugs have to be redesigned for each and every different mutation, a different key for every lock, and a different set of clinical trials for each one as well. But Diraxon Rasib doesn't work like a key. It works like a molecular glue. Instead of targeting KRAS directly, like a key for a keyhole, it binds to the outside surface of another protein called cyclofilin A. This protein is found in almost all cells. That's important because you want it to be pretty much everywhere. And together they form a surface that grabs onto KRAS or any other RAS family member when it's in the ON state. It mimics that normal binding. It mimics the normal binding partners of the ON state of RAS, but it does it even better. It's tighter, it doesn't let go. It's like super glue with a perfect fit. So once K-RAS binds, it gets stuck. Cyclofilin A, Dirac's on RASIB in the middle, and KRAS, and they all get stuck together permanently. So KRAS cannot pass this signal forward. It doesn't fit anymore. It's a dead end, and now that baton never gets handed off. The cell quits growing and multiplying. Now, because this is based only on that on-state shape and not on any specific mutations, or really any mutations at all, this allows you to block all RAS signaling and shut down cell division through this pathway. That means that it should work for most, if not all, RAS mutations, as well as anything upstream of RAS, again, like those alterations in HER2, EGFR, NF1, CSF1R, and other receptors, which are very common. This is a new approach that can be applied to many hard-to-drug targets, and that has tremendous potential. This deserves repeating. Because this approach doesn't rely on a specific mutation, it targets based on the active form of RAS, and only that form, it potentially blocks all RAS signaling. That means most KRAS mutations as well as most HRAS mutations and NRAS mutations. That's a ton of territory for one drug. Even those upstream-driven activations for non-mutated forms of RAS, that's even better. All of those are potentially covered by this one single new drug. And the implications are even bigger than just for RAS pathways. Way bigger. This is where it really gets amazing. This molecular glue strategy could be used for other undruggable targets, including MIC MYC. If that's on your genomics profile, think about this. MIC is another massive cancer driver. Over 60% of all cancers are driven by MIC issues. And it has been an incredibly hard one to design drugs for. We don't have any drugs for MIC yet, but this approach could work. So what about the results? Take a step back, take a peek at how the trial was set up and the actual data to see how it worked. The Rasolute 302 trial compared metastatic pancreatic cancer that had failed at least one previous treatment type. They had a very simple two-group design with 501 total participants. Could have been bigger, but it's still pretty good. Doraxon Rasib, that's a pill taken once a day at home as the only treatment, versus standard infusion chemotherapy of choice by the doctor. And these standard chemo treatments, they're not light treatments. They are aggressive multidrug regimens like full fox, modified fulfirinox, or gemcidabine impaclataxyl. The results? Just Diraxon Rasib created a 60% reduction in risk of death compared to the chemo. And it doubled the average survival time on treatment opposed to chemo. That is huge. Huge that it works so much better, huge again that it's a single drug, so combinations can probably improve on that. And huge once again because it is an at-home, once-a-day pill rather than an infusion, with all of the issues and complications that come with infusions. And there's even more. Diraxon Rasib crosses the blood-brain barrier. What does that mean? It means amazing things. It should work on brain metastases, and that's something that most chemotherapies cannot do. That is incredibly rare. That opens up treatment for brain meds. That's incredibly important. Now, the question everyone should be asking themselves is when can patients actually get this drug? Revolution Medicines plans to file for approval around June. They're using an FDA priority review voucher to speed things up, potentially as fast as one month for review. And the data are so good it ought to move fast. So, the best case scenario, approval by as early as July 2026. The more realistic window, somewhere between July and December of 2026, still this year. So, what can you do now? Right now there's no expanded access program yet. But there are multiple clinical trials actively recruiting. Those include trials for patients with pancreatic cancer, they're extending that, colorectal cancer, and non-small cell lung cancer. That covers a lot of folks, those three. And more importantly, most importantly, any advanced cancer with KRAS, HRAS, or NRAS mutations. That last trial is the one that will really open this up for patients. Assuming it works, and it should, that one will allow anyone with a RAS signaling defect to get Diraxon RASIB and have it covered by insurance. It won't be tied to a specific cancer, like pancreatic, but to the RAS hyperactivation biomarker. This is a great way to go. Good for you, Revolution Medicines. Now, the caveat is these current trials are all for people who have failed at least one line of treatment. Hopefully, Revolution Medicines will also start doing trials in the near future for first-line treatments. This type of targeted therapy is infinitely preferable to blunt chemotherapy like with platinum class drugs or doxorubicin. So we hope that you take advantage of these trials, and we put a link to those clinical trials down below in the citations to make it easier for you to find them and apply for them. Now, this part matters a lot. We know several people who have been declared quality of life or palliative because their oncologist doesn't believe there is anything left to do for them. Usually there are actually several options, but they're off label, and that's another discussion about the education process with oncologists. But what this means with Diraxon RASIB is that a large fraction of patients will have another very strong treatment option available if they can hold out for another three to six months. This really ought to shift what it means to be palliative if you have a RAS pathway alteration. And your oncologist should really update your plan based on that. They should be trying to get you to hang on to access that drug when it comes out because it's right around the corner. If you aren't sure whether this treatment would be helpful for you or your loved one, please reach out for an initial consultation and we can discuss the particulars. So, to recap here, this is an entirely new class of drug. This is the first intentionally designed molecular glue to probably hit the market if all goes well. It targets one of the hardest pathways in cancer. Took over 40 years to get the first drug. It works across multiple mutations, not just one. It works on overactivated, non-mutated RAS as well. This is a pill that you can take at home, not an infusion, and it crosses the blood-brain barrier. And the early data is extremely strong, really strong. And if that doesn't excite you for yourself, you should be excited for somebody else. Nearly everyone will have someone in their lives come down with a RAS-driven cancer. It is really that frequent. Maybe this isn't for you, but it will be for someone you know and you care about. If this holds up, this isn't just another drug. This is a shift in how we treat cancer. Beyond these videos, if you need more personalized guidance or a deeper dive into specific treatments to have your treatment be as effective as possible, I offer one on one sessions and medical advocacy. You can find information on our website, which is linked down below. Again, if you found this video informative, please give it a thumbs up, click the notification bell, and subscribe to our channel for more science based cancer insights.